Assessment of the Effect of Omeprazole on Vicagrel in Healthy Subjects

NCT05651074 | Unknown Phase 1 FDA Drug

• 1 other identifier: VCP1-Ⅰ-07
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of the study is to evaluate the effects of omeprazole on the PK and PD of a single dose of vicagrel in healthy subjects.

Conditions

Healthy Subjects

Outcome Measures

Primary Outcomes (4)

• Inhibition of platelet aggregation [IPA] evaluated in healthy subjects to treatment with vicagrel

  Day 2 of each period

• Platelet reactivity index [PRI] evaluated in healthy subjects to treatment with vicagrel

  Day 2 of each period

• maximum plasma concentration (Cmax)

  Up to 48 hours postdose on Day 3 for each period

• Area under the concentration-time curve (AUC)

  Up to 48 hours postdose on Day 3 for each period

Secondary Outcomes (1)

• Assess the safety of a single dose of vicagrel and a combination of vicagrel and omeprazole in healthy subjects by assessment of adverse events and symptoms and physical examination, clinical laboratory tests, vital signs,12-ECG.

  Day1-Day11

Study Arms (1)

Vicagrel and omeprazole

EXPERIMENTAL

D1 single dose of vicagrel was administered. Omeprazole administration was started on D4, once daily for 5 days, and a single dose of vicagrel and omeprazole coadministration on day 9.

Drug: Vicagrel and omeprazole

Interventions

Vicagrel and omeprazole DRUG

18 mg vicagrel capsules and 40 mg omeprazole magnesium enteric-coated tablets

Vicagrel and omeprazole

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Able and willing to give written informed consent before study, and fully understand the study content, process and possible adverse reactions;
• Able to complete the study in compliance with the protocol;
• Subject (including partner) is willing to voluntarily take effective contraceptive measures from screening through 6 months after the last dose of study drug (see Appendix 5 for details);
• Male and female subjects between the ages of 18 and 45 years, inclusive;
• At least 50 kg for male subjects, 45 kg for female subjects, with a Body Mass Index (BMI= Weight/Height2) between 18-28 kg/m2, inclusive;
• With normal or clinically insignificant abnormal results of physical examination and vital signs test;
• CYP2C19 normal metabolizers (CYP2C19\*1/\*1).

You may not qualify if:

• More than 5 cigarettes per day on average within 3 months before the study;
• History of sensitivity to drugs similar to the study drug or have high sensitivity to clopidogrel, or hypersensitivity to omeprazole, other benzimidazoles, or any excipients, allergic constitution (e.g. allergy to various drugs and foods);
• History of drug abuse, drug use, alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL beer, 25 mL spirit or 100 mL wines);
• Donation or loss of a significant volume of blood (\> 450 mL) within 3 months prior to screening;
• Intake of any prescription drugs, over-the-counter drugs, vitamin or herbal medicine within 14 days prior to receiving study drug;
• Consumption of any special diet (such as grapefruit, pitaya, mango, pomelo, etc.) or subjects have engaged strenuous exercise or any other factors affecting drug absorption, distribution, metabolism and excretion within 14 days prior to receiving study drug;
• Intake of any drug which Have taken strong inhibitors and/or inducers of liver metabolic enzymes (CYP1A2, 2A6, 2C8, 2C19, 3A4 and 3A5) within 28 days before the first medication, and strong inhibitors of liver metabolic enzymes such as: ciprofloxacin, clopidogrel, Itraconazole, ketoconazole, ritonavir, troleandomycin, etc., strong inducers of liver metabolism enzymes such as: rifampicin, carbamazepine, phenytoin sodium, St. John's wort, etc. (For details see Appendix 6);
• Recent major changes in diet or exercise habits;
• Use of an investigational drug or product, or participation in a drug research study within 3 months prior to receiving study drug;
• History of difficulties in swallowing, or any gastrointestinal disease which could affect the drug absorption;
• Suffering from any diseases that may increase the risk of bleeding, such as hemorrhoids, acute gastritis, stomach and duodenal ulcers, Thrombocytopenic Purpura and hemophilia, etc;
• Family history of coagulation or bleeding disorders (e.g., hemophilia)/symptoms (e.g., vomiting blood, black stools, severe or recurrent nosebleeds, coughing up blood, significant hematuria, or intracranial hemorrhage) or suspected vascular malformations, such as aneurysms or early onset strokes, in the individual or in their immediate family;
• A clinically significant 12-lead ECG abnormality;
• Positive test results of blood pregnancy or subject is lactating for female subjects;
• Any clinically significant abnormalities/findings in laboratory tests, or any clinically significant disease including but not limited to gastrointestinal, renal, hepatic, neurological system, blood, endocrine, tumor, lung, immune, mental, or cardiovascular and cerebrovascular diseases;

Sponsors & Collaborators

• Jiangsu vcare pharmaceutical technology co., LTD: lead

Study Sites (1)

Phase I Clinical Research Center of The First Hospital of Jilin University

Changchun, Jilin, China

RECRUITING

MeSH Terms

Interventions

methyl 2-(2-acetoxy-6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl)-2-(2-chlorophenyl)acetate; Omeprazole

Intervention Hierarchy (Ancestors)

2-Pyridinylmethylsulfinylbenzimidazoles; Sulfoxides; Sulfur Compounds; Organic Chemicals; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Benzimidazoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Central Study Contacts

Wang Fei, 130021

CONTACT

0431-88786014; wangfei5780@126.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 17, 2022
• First Posted: December 14, 2022
• Study Start: November 14, 2022
• Primary Completion: February 1, 2023
• Study Completion: April 1, 2023
• Last Updated: January 31, 2023

Record last verified: 2022-11

Locations

CN (1)